Biomarker Discovery and Machine Learning in Large Pharmacogenomics Datasets

Arvind Singh Mer,

Zhaleh Safikhani,

Petr Smirnov,

Benjamin Haibe-Kains

Princess Margaret Cancer Center,University Health Network

University of Toronto, Canada

OBJECTIVES

- Know the basics of different preclinical models used in cancer precision medicine

- Understand the role of pharmacogenomics in cancer precision medicine

- Know about different cancer pharmacogenomics datasets and projects

- Perform validation of biomarkers using publically available datasets

- Build machine learning models to predict anticancer drug response

Please don't forget to fill the feedback form!

https://goo.gl/forms/0sR1kfVO6nj4X8bO2

BHK
LAB

References

- CMAP: Lamb, J. et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science 313, 1929–1935 (2006).
- L1000: Subramanian, A. et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171, 1437-1452.e17 (2017).
- CCLE: Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
- CTRPv2: Seashore-Ludlow, B. et al. Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. Cancer Discovery (2015). doi:10.1158/2159-8290.CD-15-0235
- GDSC1000: Lorio, F. et al. A Landscape of Pharmacogenomic Interactions in Cancer. Cell 166, 740–754 (2016).
- BeatAML: Tyner, J. W. et al. Functional genomic landscape of acute myeloid leukaemia. Nature 562, 526 (2018).
- Samsung Patient Derived Tumour Cells: Lee, J.-K. et al. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy. Nature Genetics 50, 1399 (2018).
- Novartis PDXE: Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nature Medicine 21, 1318–1325 (2015).
- PharmacoDB: Smirnov, P. et al. PharmacoDB: an integrative database for mining in vitro anticancer drug screening studies. Nucleic Acids Res 46, D994–D1002 (2018).
- Cell Miner CDB: Rajapakse, V. N. et al. Integrative analysis of pharmacogenomics in major cancer cell line databases using CellMinerCDB. bioRxiv 292904 (2018). doi:10.1101/292904
- Xeva: Mer, et al. "Integrative pharmacogenomics analysis of patient-derived xenografts." Cancer research (2019)

BHK LAB

Acknowledgements

BHK Lab

Princess Margaret Cancer Centre

Questions

Please don't forget to fill the feedback form!

https://goo.gl/forms/0sR1kfVO6nj4X8bO2

Arvind Mer	a.mer@utoronto.ca	@ArvidMer
Zhaleh Safikhani	zhaleh.safikhani@utoronto.ca	@Zhaleh_julie
Petr Smirnov	petr.smirnov@mail.utoronto.ca	@ _psmirnov

BHK LAB